PharmaDeals Review
PharmaDeals Review (ISSN 1756-7874 online publication) is an electronic publication that augments the PharmaDeals v2 database to provide expert opinion and analyses. Unlike print publications, our expert editorial team publishes their articles immediately and continuously, ensuring you get vital deal information and analyses at the very earliest opportunity.
The three latest articles are listed below. View all the current Review articles using the Current Review Articles link to the right. Older Review articles (pdf format only) are available in the archive.
Merrion to Develop Insulin Drugs with Novo
2008-11-24
Novo Nordisk signed an agreement to develop oral insulin analogues using Merrion Pharmaceuticals’ Gastrointestinal Permeation Enhancement Technology (GIPET) in a deal valued at €45 M (US$58 M). Novo Nordisk is seeking alternative strategies for diabetes after abandoning its inhaled insulin product.
Johnson & Johnson Strengthens its Biosurgical Position by Acquiring Omrix
2008-11-24
Johnson & Johnson (J&J) has gained a series of innovative biosurgical products with its acquisition of Omrix, its partner of five years, for US$438 M. The two companies already have a marketing agreement for Omrix’s flagship product, but with this acquisition, J&J can now use its marketing skills to sell other Omrix products while Omrix focuses on developing novel biosurgical products.
Cash-strapped TorreyPines Divests its Alzheimer’s Disease Developments
2008-11-18
In order to raise cash to progress its clinical developments, TorreyPines Therapeutics is disposing its Alzheimer’s developments through two recently signed deals. The beneficiaries are Eisai, which has acquired the genetics programme, and QR Pharma, which has licensed worldwide rights to three compounds, Posiphen™, bisnorcymcerine and phenserine.
PharmaDeals Review features:
PharmaDeals analyses specific deals and examines trends and developments within deal making in different technology and therapy areas. It also assess data from the PharmaDeals v2 database, as well as many other sources of information and the in-house knowledge base available to our expert team of writers.
- Deal trackers articles where late phase and recently launched products are explored from the perspective of the deals done to bring them through development, offering insight into the complex alliance history of individual drugs
- Deal analysis and opinion from our expert team of writers
- Business commentary – The Publisher and CEO Dr Fintan Walton comments on topical industry issues and how they may impact on deal making
- Feature articles from the industry’s thought leaders offering in-depth analysis of the key developments within deal making
- Global companies' deal watch
- Conference calendar – specially selected conferences
- Yearly analysis: Summary of the year and comment prospective, future trends
In addition, your subscription includes the entire PharmaDeals Review Article Archive – hundreds of articles all links to specific deals recorded in the PharmaDeals v2 database
Subscribers to PharmaDeals v2, receive PharmaDeals Review at no additional cost.
Review and Analysis, Navigation
Bookmarks
Bookmark PharmaDeals through one of these social networks.
